MedWatch

Sunstone increases share in Swedish biotech company

The Swedish biotech company Cantagia issues new shares for SEK 232 million (USD 27.71 million) and the major investor Sunstone Capital takes the opportunity to increase its investments in the company that aims for going public on Nasdaq Stockholm in 2018.

On an extraordinary general meeting in the Swedish biotech company Cantargia, the shareholders approved the management’s plans on financing the company’s expanded clinical program by issuing new shares for altogether SEK 232 million (USD 27.71 million).

The existing shareholders in Cantagia count for instance the venture capital fund Sunstone Capital that invested SEK 4 million in the company back in 2013. And the fund is so confident in the Swedish company that it pumps SEK 25 million more into Cantargia that is based in the university town Lund.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier